Skip to main content
Fig. 1 | BMC Complementary Medicine and Therapies

Fig. 1

From: 6-Shogaol enhances the anticancer effect of 5-fluorouracil, oxaliplatin, and irinotecan via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions

Fig. 1

Results of cell viability measured by MTT assay of cell lines. a Dose-depended bars for SW480, SW620, WI38 cells after 48 h incubation with 6-shogaol. b SW480 cell line viability in normoxia conditions (21% of oxygen, 5% CO2, medium with glucose) and hypoxic conditions (1% of oxygen, 5% CO2, glucose-free medium) after 48 h of incubation with 6-shogaol (25 μM), different chemotherapeutics (FU 125 μM, IRI 75 μM, OXA 50 μM) alone and in combination with 6-shogaol. c SW620 cell line viability in normoxia conditions (21% of oxygen, 5% CO2, medium with glucose) and hypoxic conditions (1% of oxygen, 5% CO2, glucose-free medium) after 48 h of incubation with 6-shogaol (25 μM), different chemotherapeutics alone (FU 125 μM, IRI 75 μM, OXA 50 μM) and in combination with 6-shogaol. Control-cells incubated in a complete culture medium, Shogaol- 6-shogaol, FU-fluorouracil, IRI-irinotecan, OXA-oxaliplatin, medium with glucose (G+), glucose-free medium (G-). Bars show mean from three experiments. * p < 0.05

Back to article page